Search research articles
Contact Us
Filters
Showing results (41-50 of 63) with videos related to
Page
of 7
Sort By:
Blood Cancer Journal
|
August 29, 2025
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
Giulio Cassanello, Esther Drill, Annie Qiu, et al.
Annals of Hematology
|
July 11, 2023
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Blood Advances
|
January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
Erel Joffe, Yan Leyfman, Esther Drill, et al.
Blood Advances
|
August 2, 2023
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study
Bradley Haverkos, Onder Alpdogan, Robert Baiocchi, et al.
Annals of Hematology
|
May 12, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Blood Advances
|
September 16, 2021
Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?
Brandon S Imber, Karen W Chau, Jasme Lee, et al.
Haematologica
|
August 30, 2023
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes
Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, et al.
Transplantation and Cellular Therapy
|
October 13, 2024
Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study
Ron Ram, Odelia Amit, Chava Perry, et al.
Blood
|
February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
Sven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Cancers
|
March 29, 2023
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting
Serena Zheng, Kanika Gupta, Piyush Goyal, et al.
Page
of 7
Search research articles
Search
Showing results (41-50 of 63) with videos related to
Sort By:
Page
of 7
Blood Cancer Journal
|
August 29, 2025
Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era
Giulio Cassanello, Esther Drill, Annie Qiu, et al.
Annals of Hematology
|
July 11, 2023
Correction to: RE‑MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola‑BR), CAR‑T therapies, and lenalidomide/rituximab (R2) based on real‑world data in patients with relapsed/refractory diffuse large B‑cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Blood Advances
|
January 26, 2021
Active surveillance of primary extranodal marginal zone lymphoma of bronchus-associated lymphoid tissue
Erel Joffe, Yan Leyfman, Esther Drill, et al.
Blood Advances
|
August 2, 2023
Targeted therapy with nanatinostat and valganciclovir in recurrent EBV-positive lymphoid malignancies: a phase 1b/2 study
Bradley Haverkos, Onder Alpdogan, Robert Baiocchi, et al.
Annals of Hematology
|
May 12, 2023
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma
Grzegorz S Nowakowski, Dok Hyun Yoon, Patrizia Mondello, et al.
Blood Advances
|
September 16, 2021
Excellent response to very-low-dose radiation (4 Gy) for indolent B-cell lymphomas: is 4 Gy suitable for curable patients?
Brandon S Imber, Karen W Chau, Jasme Lee, et al.
Haematologica
|
August 30, 2023
Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes
Paola Ghione, Salma Ahsanuddin, Efrat Luttwak, et al.
Transplantation and Cellular Therapy
|
October 13, 2024
Addition of Nivolumab Tailored by Expansion of CAR-T Cells in Patients with Stable/Progressive Large B Cell Lymphoma at Lymphodepletion-A Phase 2, Prospective Interventional Study
Ron Ram, Odelia Amit, Chava Perry, et al.
Blood
|
February 17, 2019
Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma
Sven Borchmann, Erel Joffe, Craig H Moskowitz, et al.
Cancers
|
March 29, 2023
Outcomes of Patients with Positive Interim Positron Emission Tomography (PET) Continuing ABVD in the Clinical Setting
Serena Zheng, Kanika Gupta, Piyush Goyal, et al.
Page
of 7